Literature DB >> 23047687

Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002.

Claudia Allemani1, Pamela Minicozzi, Franco Berrino, Esther Bastiaannet, Anna Gavin, Jaume Galceran, Alberto Ameijide, Sabine Siesling, Lucia Mangone, Eva Ardanaz, Guy Hédelin, Antonio Mateos, Andrea Micheli, Milena Sant.   

Abstract

Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of 10-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at 1, 5, and 10 years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated 10-year survival conditional on survival to 1 and 5 years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for 1 year was 2-6% higher than 10-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least 5 years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 23047687     DOI: 10.1002/ijc.27895

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

Authors:  Brigitte Rack; Julia Jückstock; Elisabeth Trapp; Tobias Weissenbacher; Marianna Alunni-Fabbroni; Amelie Schramm; Peter Widschwendter; Krisztian Lato; Thomas Zwingers; Ralf Lorenz; Hans Tesch; Andreas Schneeweiss; Peter Fasching; Sven Mahner; Matthias W Beckmann; Werner Lichtenegger; Wolfgang Janni
Journal:  Tumour Biol       Date:  2016-08-01

Review 2.  Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.

Authors:  Nigel Fleeman; Adrian Bagust; Sophie Beale; Kerry Dwan; Rumona Dickson; Chris Proudlove; Yenal Dundar
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

3.  Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis.

Authors:  Asami Yagi; Yutaka Ueda; Sayaka Ikeda; Ai Miyoshi; Satoshi Nakagawa; Kosuke Hiramatsu; Eiji Kobayashi; Toshihiro Kimura; Yuri Ito; Tomio Nakayama; Kayo Nakata; Toshitaka Morishima; Isao Miyashiro; Tadashi Kimura
Journal:  Int J Cancer       Date:  2021-09-15       Impact factor: 7.316

4.  Comparison of brachytherapy and external beam radiotherapy boost in breast-conserving therapy: Patient-reported outcome measures and aesthetic outcome.

Authors:  I Kindts; A Laenen; M Christiaens; H Janssen; E Van Limbergen; C Weltens
Journal:  Strahlenther Onkol       Date:  2018-08-23       Impact factor: 3.621

5.  SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.

Authors:  Kimberly D van der Willik; Mieke M Timmermans; Carolien Hm van Deurzen; Maxime P Look; Esther A Reijm; Wendy Jhp van Zundert; Renée Foekens; Anita Mac Trapman-Jansen; Michael A den Bakker; Pieter J Westenend; John Wm Martens; Els Mjj Berns; Maurice Phm Jansen
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

6.  Clinical implications of multifocality as a prognostic factor in breast carcinoma - a multivariate analysis study comprising 460 cases.

Authors:  Monica Boros; Septimiu Voidazan; Cosmin Moldovan; Rares Georgescu; Cornelia Toganel; Denisa Moncea; Claudiu V Molnar; Cristian Podoleanu; Alexandru Eniu; Simona Stolnicu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data.

Authors:  Yuri Ito; Isao Miyashiro; Hidemi Ito; Satoyo Hosono; Dai Chihara; Kayo Nakata-Yamada; Masashi Nakayama; Masashi Matsuzaka; Masakazu Hattori; Hiromi Sugiyama; Isao Oze; Rina Tanaka; Etsuko Nomura; Yoshikazu Nishino; Tomohiro Matsuda; Akiko Ioka; Hideaki Tsukuma; Tomio Nakayama
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

8.  Conditional survival for longer-term survivors from 2000-2004 using population-based cancer registry data in Osaka, Japan.

Authors:  Yuri Ito; Tomio Nakayama; Isao Miyashiro; Akiko Ioka; Hideaki Tsukuma
Journal:  BMC Cancer       Date:  2013-06-22       Impact factor: 4.430

9.  Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.

Authors:  Rudolf Weide; Stefan Feiten; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Jörg Thomalla; Christoph van Roye; Hubert Köppler
Journal:  Springerplus       Date:  2014-09-17

10.  Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.

Authors:  S De Placido; C De Angelis; M Giuliano; C Pizzi; R Ruocco; V Perrone; D Bruzzese; G Tommasielli; M De Laurentiis; S Cammarota; G Arpino; G Arpino
Journal:  Br J Cancer       Date:  2017-02-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.